Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCHW) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Envoy Medical (COCHW) over the last 4 years, with Q3 2025 value amounting to -$7.7 million.

  • Envoy Medical's Net Income towards Common Stockholders fell 554.5% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.6 million, marking a year-over-year decrease of 782.38%. This contributed to the annual value of -$28.0 million for FY2024, which is 1054.31% up from last year.
  • As of Q3 2025, Envoy Medical's Net Income towards Common Stockholders stood at -$7.7 million, which was down 554.5% from -$6.9 million recorded in Q2 2025.
  • Envoy Medical's 5-year Net Income towards Common Stockholders high stood at $18.0 million for Q2 2022, and its period low was -$13.3 million during Q1 2023.
  • For the 4-year period, Envoy Medical's Net Income towards Common Stockholders averaged around -$4.3 million, with its median value being -$6.9 million (2025).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 20485.44% in 2023, then plummeted by 62279.2% in 2024.
  • Envoy Medical's Net Income towards Common Stockholders (Quarter) stood at -$11.5 million in 2022, then skyrocketed by 45.34% to -$6.3 million in 2023, then dropped by 22.96% to -$7.7 million in 2024, then fell by 0.44% to -$7.7 million in 2025.
  • Its last three reported values are -$7.7 million in Q3 2025, -$6.9 million for Q2 2025, and -$6.2 million during Q1 2025.